Assessing the Benefits, Risks, and Long-Term Metabolic Effects of GLP-1 ...
Feb 24, 2025As the popularity ofGLP-1(Glucagon-Like Peptide-1) agonists. including semaglutide - branded as Wegovy or Ozempic, and tirzepatide (dual GIP/GLP-1 receptor agonist) - branded as Zepbound or Mounjaro, for the management of obesity, type 2 diabetes, and other metabolic conditions increases, so too does the need to assess the advantages and potential downsides of long-term use. While these ...
source: https://drbojana.com